Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2001

View Archived Issues

NC-381 shows potential inhibitory effects on prostate tumor growth in preclinical studies

Early data from NHL patients treated with CpG-7909 indicate good safety, immunostimulatory effects

Potential of CP-461 in CLL supported by laboratory research discussed at ASH meeting

Valrocemide characterized as a safe, broad-spectrum anticonvulsant agent

Mechanism of anticonvulsant action of CGX-1007, an NMDA antagonist, explored

Retigabine appears not to interfere with low-dose oral contraceptives

Zonegran effective and safe as monotherapy in partial seizures

Repifermin continues to show excellent safety profile in phase II trials for various indications

Amsterdam Molecular Therapeutics receives grant for LPL gene therapy

Excellent safety, evidence of activity for beta-alethine in immunocompetent lymphoma patients

First phase III trial of AC-2993 for type 2 diabetes under way

Synsorb discontinues Synsorb-Cd development program

Initiation of second phase I trial of Triapine in advanced leukemia

Endovasc submits revised phase III protocol for Liprostin; requests FDA meeting

Microbiotix obtains exclusive worldwide license to novel antiviral compounds

Notice of allowance of patent for once-daily Cidecin dosing regimen

Wide series of macrocyclic compounds for HCV designed and disclosed in recent patent

CXCR1/CXCR2 receptor antagonists in the GSK pipeline

Definity launched in North American markets for contrast enhancement in echocardiography

Inhibitors of VEGF receptor tyrosine kinase and their use described by AstraZeneca

New piperidines described in patent literature act as NK1 receptor antagonists

Somatostatin sst2 receptor antagonists synthesized at Pfizer elevate GH secretion

Novartis presents potent new PDE5 inhibitors for erectile dysfunction

Tyrosine kinase inhibitors useful in cancer Rx designed at Boehringer Ingelheim

CPMP recommends approval of Dynepo for anemia of renal failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...